

Identifying the Right Investigators with Sitetrove

Accelerate your cycle times by selecting investigators with experience and access to potential patients for your trial

STUDY PROFILE


Disease: Non-small cell lung cancer

Intervention: Investigational regimen with adjuvant therapy

Target Country: United States

Locating investigators experienced in studies with adjuvant therapy in non-small cell lung cancer (NSCLC)

-  **Sitetrove Search Criteria:**
-  Disease: Lung, Non-small cell (NSCLC)
-  Location: United States
-  Patient Segment: Adjuvant
-  Investigator Tier: 1




It is vital to identify the best investigators with experience conducting trials that match your study protocol. 1,933 US-based investigators experienced in adjuvant NSCLC trials were found in Sitetrove.

Leveraging the Investigator Tiering prioritization tool enables quick identification of Tier 1 investigators, who are those with the highest likelihood to perform well in a trial within the given disease, on average and as a group, compared with investigators in Tiers 2 or 3. A total of 405 matching investigators are designated as a Tier 1.

Source: Sitetrove, October 2020

Incorporating patient volumes into your investigator identification process

- Sitetrove Search Criteria:**
- ▶ Disease: Lung, Non-small cell (NSCLC)
 - ▶ Location: United States
 - ▶ Investigator Tier: 1
 - ▶ Investigator Patient Count: 100 patients or more



To further inform your analysis, an investigator's potential patient reach can be assessed based on claims data from the last 24 months, also available within Sitetrove.

Removing the Adjuvant Patient Segment expands the search to Tier 1 investigators who have seen NSCLC patients in the last two years, including those that may potentially be eligible for your trial.


458 Tier 1 NSCLC investigators have seen at least 100 NSCLC patients in the last two years.

Source: Sitetrove, October 2020

Honing in on the ideal pool of investigators

The results can then be compared to identify the overlapping investigators, drilling down to the group of investigators with the right experience and access to the right potential patients.

An overlap of 285 US-based investigators are designated as Tier 1 investigators experienced with adjuvant therapy trials AND have seen at least 100 NSCLC patients in the last two years.



Source: Sitetrove, October 2020

Sitetrove enables you to quickly drill down its industry leading data and identify qualified investigators with the highest potential to perform and access to specific patient population, saving time while selecting investigators that can help your trial succeed.



To learn more about Sitetrove and the advantages we can deliver to your company, please visit: pharmaintelligence.informa.com or email: Pharma@informa.com

US Toll-Free: +1 888-670-8900 US Toll: +1 908-547-2200 UK & Europe: +44 (0) 203 377 3737 Australia: +61 2 8705 6907

SITETROVE-0243-CASESTUDY-001-NOV20-HR